Advances in the treatment of Alzheimer's disease

American Family Physician

Volumn 58, Issue 7, 1998, Pages 1577-1586

  Sloane, Philip D ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DONEPEZIL; ESTROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; TACRINE;

ALZHEIMER DISEASE; ARTICLE; CAREGIVER; DIFFERENTIAL DIAGNOSIS; DRUG INDICATION; FAMILY COUNSELING; HEALTH CARE DELIVERY; HUMAN; LIVING WILL; MULTIINFARCT DEMENTIA; PATIENT CARE;

ALGORITHMS; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLINESTERASE INHIBITORS; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ESTROGENS; HUMANS; MENTAL DISORDERS; TERMINAL CARE; VITAMIN E;

EID: 0032212904     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
2. Agency for Health Care Policy and Research. Recognition and initial assessment of Alzheimer's disease and related dementias. Clinical practice guideline no. 19. Rockville, Md.: Dept. of Health and Human Services, Public Health Services, 1996; AHCPR publication no. 97-0702.
3. Whitehouse PJ. Genesis of Alzheimer's disease. Neurology 1997;48(5 Suppl 7):S2-7.
4. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997;275:630-1.
5. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996;347:1091-5.
6. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
7. Filley CM. Alzheimer's disease: it's irreversible but not untreatable. Geriatrics 1995;50:18-23.
8. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50: 1214-21.
9. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer's disease. Lancet 1997;350:232-3.
10. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
11. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med 1996;156:2213-7.
12. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study on Aging. Neurology 1997;48:1517-21.
13. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
14. Rozzini R, Ferrucci L, Losonczy K, Havlik RJ, Guralnik JM. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc 1996;44:1025-9.
15. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154(5 Suppl):1-39 [Published erratum appears in Am J Psychiatry 1997;154:1180].
16. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
17. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327-32.
18. Burns A, Murphy D. Protection against Alzheimer's disease? Lancet 1996;348:420-1.
19. Mor V, Banaszak-Holl J, Zinn J. The trend toward specialization in nursing care facilities. Generations 1996;19:24-9.
20. Phillips CD, Sloane PD, Hawes C, Koch G, Han J, Spry K, et al. Effects of residence in Alzheimer disease special care units on functional outcomes. JAMA 1997;278:1340-4 [Published erratum appears in JAMA 1998;279:1376-7].
21. Ferrell BA, Ferrell BR, Rivera L. Pain in cognitively impaired nursing home patients. J Pain Symptom Manage 1995;10:591-8.
22. Mitchell SL, Kiely DK, Lipsitz LA. The risk factors and impact on survival of feeding tube placement in nursing home residents with severe cognitive impairment. Arch Intern Med 1997;157:327-32.
23. Hall GR. Examining the end stage: what can we do when we can't do any more? [Editorial] J Gerontol Nurs 1991;17:3-4.
24. McCann RM, Hall WJ, Groth-Juncker A. Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994;272:1263-6.
25. Alzheimer's Association. Care for advanced Alzheimer's disease. Chicago: Alzheimer's Association, 1994.
26. Besdine RW, Jarvik LF, Tangalos EG. Managing advanced Alzheimer's disease. Patient Care 1991; 25:75-100.